Endocrine therapy, with or without the use of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is the current standard of care for patients with advanced hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer [1,2]. This evidence concerns the gene ERBB2 and breast carcinoma.